Peter Jarrett, Lexington, MA (US); Michael J. McGrath, Upton, MA (US); Timothy S. Jarrett, Boston, MA (US); Rami El-Hayek, Norwood, MA (US); Andrew C. Vanslette, Medford, MA (US); Courtney A Rosales, Ipswich, MA (US); Charles D. Blizzard, Nashua, NH (US); and Amarpreet S. Sawhney, Lexington, MA (US)
Assigned to Incept, LLC, Lexington, MA (US)
Filed by Incept, LLC, Lexington, MA (US)
Filed on Jul. 7, 2022, as Appl. No. 17/859,820.
Application 17/859,820 is a continuation of application No. 16/999,504, filed on Aug. 21, 2020, granted, now 11,413,250.
Application 16/999,504 is a continuation of application No. 16/533,331, filed on Aug. 6, 2019, granted, now 10,786,462, issued on Sep. 29, 2020.
Application 16/533,331 is a continuation of application No. 15/360,430, filed on Nov. 23, 2016, granted, now 10,420,724, issued on Sep. 24, 2019.
Claims priority of provisional application 62/260,068, filed on Nov. 25, 2015.
Claims priority of provisional application 62/319,033, filed on Apr. 6, 2016.
Prior Publication US 2022/0339108 A1, Oct. 27, 2022
1. A method of ocular delivery of a therapeutic agent to a patient comprising introducing a device for drug delivery to an ocular placement site, wherein the device comprises a therapeutic agent disposed in a solid vehicle that comprises a first xerogel and a second xerogel, wherein the first xerogel is a rod and the second xerogel is a layer on the first xerogel, wherein the first xerogel and the second xerogel differentially swell and/or elongate to change the rod into a curve shape in response to a physiological fluid of the ocular placement site, wherein the solid vehicle provides a controlled release of the therapeutic agent.
